Recently we showed an integral epidermal growth factor receptor (EGFR)-E2F3a signaling path, in which E2F3a was found to be essential in EGFR-mediated proliferation in ovarian cancer cells. The present work evaluates the clinical relevance of this novel axis and of E2F3a itself in a large set of 130 ovarian cancer specimens. For this purpose E2F3a and its counterpart, E2F3b, were measured by RT-PCR and activated EGFR was assessed by immunohistochemistry. When compared with healthy control tissue, both E2F3 isoforms were overexpressed in the cancers, but only E2F3a expression correlated with tumor stage (q ¼ 0.349, P ¼ 0.0001) and residual disease (q ¼ 0.254, P ¼ 0.004). Univariate survival analyses showed E2F3a and activated EGFR to be associated with poor PFS and OS. Furthermore, a strong, positive correlation between activated EGFR and E2F3a expression was shown (P ¼ 0.0001). We further identified two EGFR-independent mechanisms that regulate E2F3a expression, namely one, acting by promoter methylation of miR-34a, which by its physical interaction with E2F3a transcripts causes their degradation, and the second based on 6p22 gene locus amplification. MiRIDIAN-based knockdown and induction of miR-34a evidenced a direct regulatory link between miR-34a and E2F3a, and the tumor-suppressive character of miR-34a was documented by its association with improved survival. Although, 6p22 gene locus amplification was detected in a significant number of ovarian cancer specimens, 6p22 ploidy was not relevant in predicting survival. In Cox regression analysis, E2F3a, but not activated EGFR or miR-34a expression, retained independent prognostic significance (PFS: hazards ratio 3.785 (1.326-9.840), P ¼ 0.013; OS: hazards ratio 4.651 (1.189-15.572), P ¼ 0.013). These clinical findings highlight the relevance of E2F3a in the biology of ovarian cancer. Moreover, identification of EGFR-independent mechanisms in E2F3a control can be helpful in explaining the non-responsiveness of therapeutic EGFR targeting in ovarian cancer.
Introduction
Ovarian cancer is the most lethal gynecological cancer in Western countries. Despite sufficient first-line treatment, 5-year overall survival (OS) remains unacceptably low due to the high incidence of early recurrence and the development of platinum resistance (Markman, 2008) . Thus, alternative treatment strategies, including targeting of relevant cancer-associated pathways, are clearly warranted. In this context, selective targeting of epidermal growth factor receptor (EGFR) poses an appealing new approach in cancer treatment, having already reached the 'bedside.' Numerous studies have been published with regard to EGFR expression in ovarian cancer and have shown expression in up to 88% of ovarian cancers (Stadlmann et al., 2006) . The EORTC together with several gyneco-oncologic groups worldwide has launched a large randomized trial to investigate the role of erlotinib in maintenance therapy in ovarian cancer (http://groups.eortc.be/gcg/). However, recent results from phase-II trials on the direct targeting of EGFR in ovarian cancer were disappointing, with low response rates of 4 and 6% for cetuximab and erlotinib, respectively (Gordon et al., 2005; Schilder et al., 2009) . This justifies the question whether distinct downstream components of the EGFR cascade are aberrantly activated in ovarian carcinomas.
We recently reported the existence of a novel EGFR molecular pathway, which through its key player E2F3a, a proliferation-promoting member of the E2F family of transcription factors (Paulson et al., 2006; Chen and Wells, 2007) , is crucially involved in ovarian cancer cell proliferation (Reimer et al., 2010) . This leads us to pose the hypothesis that an as yet undiscovered EGFR-E2F3a 'fast track' involving the mutually antagonistic interferon-regulatory factors 1 (IRF-1) and 2 (IRF-2) commonly exists in ovarian cancer. This assumption is based on the following in vitro findings: (i) EGF treatment of ovarian cancer cells causes a selective upregulation of E2F3a without affecting the expression of any other E2F family members; (ii) the extent of the EGF-induced stimulation of cancer cell growth was faithfully mirrored by the magnitude of E2F3a induction and both were reversed by EGFR-inhibiting drugs; (iii) short interfering RNA-based knockdown of E2F3a yielded a significant inhibition of EGF-induced proliferation in ovarian cancer cell lines; and (iv) the shift in the IRF-1:IRF-2 ratio toward IRF-2 caused by EGF stimulation is crucially involved in E2F3a induction.
The objective of the present study is first to evaluate the clinical impact of this recently discovered EGFR signaling pathway in ovarian cancer, and second to validate the clinical significance of alternative EGFRindependent mechanisms modulating E2F3a that were found to be essentially involved in ovarian cancer cell proliferation. For this purpose, expression levels of E2F3 isoforms and activated EGFR status were assessed in 130 primary ovarian cancer specimens and compared with the most relevant clinicopathological features of the disease and estimated for their prognostic relevance. Within this collective a subgroup of patients was distinguishable showing EGFR-independent regulation of E2F3a expression. This led us to identify two alternative mechanisms in terms of miR-34a promoter methylation and 6p22 gene locus amplification, which emerged to be also pivotally involved in the aberrant expression of E2F3a in epithelial ovarian carcinomas.
Results
Expression of E2F3a and E2F3b, and its relationship to clinicopathological parameters and activated EGFR in primary ovarian cancers In order to evaluate the clinical relevance of the postulated EGF-E2F3a axis in ovarian cancer, expression of E2F3a and E2F3b mRNA was assessed in 130 ovarian cancer specimens and 35 samples of normal ovarian tissue. The median expression levels of both E2F3 isoforms were significantly higher in the tumors than in the healthy controls (E2F3a: 2.97 versus 0.22, P ¼ 0.0001; E2F3b: 1.19 versus 0.34, P ¼ 0.0001). Median expression of E2F3a in cancer specimens was significantly higher than that of E2F3b (P ¼ 0.0001), whereas in controls E2F3b expression exceeded that of E2F3a (P ¼ 0.005). Regarding the classic clinicopathological parameters, both E2F3 isoforms correlated positively with histopathological grading (E2F3a: r ¼ 0.471, P ¼ 0.0001; E2F3b: r ¼ 0.308, P ¼ 0.001), whereas only E2F3a transcript levels were positively associated with FIGO stage and with residual disease (r ¼ 0.349, P ¼ 0.0001 and r ¼ 0.254, P ¼ 0.004, respectively). It is noteworthy that E2F3a and E2F3b levels were equally distributed regarding different histological subtypes.
Furthermore, in this cohort of 130 cancers a highly significant positive correlation between activated EGFR and E2F3a expression was shown (r ¼ 0.8914, P ¼ 0.0001) (Figure 1 ). However, we detected a subgroup of 14 patients (11%) that showed high E2F3a expression, but was immunohistochemically negative for activated EGFR.
Prognostic impact of E2F3 isoforms and activated EGFR in ovarian cancer
To evaluate a putative prognostic relevance of both E2F3 isoforms, our data set was subjected to survival analysis. As expected, FIGO stage, histological grading, patient age at diagnosis and residual disease after primary surgery significantly influenced progression-free (PFS) and OS (Table 1) . Of special note is the finding that activated EGFR status is associated with poor PFS (P ¼ 0.020) and OS (P ¼ 0.033) in univariate survival analyses (Figures 2a and b) . When patients were dichotomized according to E2F3a expression, E2F3a levels above the median value were associated with unfavorable PFS (P ¼ 0.0001) and OS (P ¼ 0.0001) (Figures 2c and d) . Median time to progression in the high E2F3a group was 18 months (15.5-20.5) and median OS was 39 months (30.9-47.1). No significant difference in survival was assessed in groups with low or high E2F3b expression (PFS: P ¼ 0.099, OS: P ¼ 0.077).
Alternative mechanisms regulating E2F3a in ovarian cancer
The observation of a subgroup of patients showing high E2F3a transcript levels without detectable EGFR activation prompted us to explore whether alternative mechanisms, such as epigenetic regulation by E2F3a promoter DNA methylation, microRNA (miRNA) interactions or even promoter DNA methylation of microRNAs, are critical in governing E2F3a expression in ovarian cancer.
CpG clusters located between À1004 and À207 were detectable in the E2F3a promoter, whereas no relevant CpG islands were found within the E2F3b promoter region. However, significant DNA methylation of E2F3a was detected in only one patient (1%) using two different primer sets in the MethyLight analysis. Figure 1 Correlation between activated EGFR status and high E2F3a expression levels in primary ovarian cancer specimens (n ¼ 130). The majority of ovarian cancer specimens showed a high correlation between phosphorylated EGFR and the level of E2F3a expression. However, a subgroup of patients without detectable EGFR activation exhibited E2F3a mRNA levels above the median (n ¼ 14) (D). EGFR, epidermal growth factor receptor. Determination of known E2F-regulating miRNAs, namely miR-20a, miR-210 and miR-34a, showed that only miR-34a expression negatively correlated with E2F3a mRNA levels. Considering DNA methylation of the respective promoters miR-34a, miR-210 and miR-20a, again only methylated miR-34a promoter correlated with E2F3a mRNA levels ( Table 2) . DNA methylation of the miR-34a promoter was observed in 24% of the cases and within this group 15 patients (12%) showed concomitant EGFR activation. However, in the subgroup of patients showing an obvious EGFRindependent E2F3a increase, 73% of tumors showed miR-34a promoter methylation. Taken together, our data point to an alternative post-transcriptional control of E2F3a, namely by promoter DNA methylation and subsequent silencing of the E2F3a-repressing miR-34a.
Clinical impact of E2F3a in ovarian cancer
As miR-34a expression was shown to be directly induced by p53, we additionally found that tumors with documented inactivating p53 mutations (n ¼ 47) showed significantly lower levels of miR-34a (median values: 0.76 versus 0.39, P ¼ 0.0001) and significantly higher E2F3a transcript levels (median values: 0.89 versus 3.60, P ¼ 0.0001) than p53 wild-type tumors.
Proof-of-principle experiments showing E2F3a regulation by miR-34a promoter methylation
In order to verify the herein postulated direct regulatory function of miR-34a promoter methylation in modulating E2F3a expression, we studied miR-34a and E2F3a expression in ovarian cancer cell lines (A2780, HTB77
and HOC-7) grown under demethylating conditions. The most prominent effect was observed in low-EGFRexpressing A2780 cells (Figures 3a-c) . 5-Aza-2 0 deoxycytidine (5-AZA) treatment yielded a significant decrease in miR34a promoter methylation and a 13-fold induction of miR-34a expression. This effect came along with simultaneous downregulation of E2F3a, whereas E2F3b transcript levels remained unchanged. A similar but less pronounced effect was observed in HTB-77 (Figures 3d-f ). HOC-7 cells, however, did not show 5-AZA-induced E2F3a depletion. This was in line with our finding that in this cell line we were unable to detect methylation of the CpG island in the miR-34a promoter. When ovarian cancer cell lines were treated with the histone deacetylase inhibitor trichostatin-A (TSA) alone, no significant changes in either miR-34a or E2F3 isoform expression were detectable. The E2F3a promoter itself was not methylated in any of the investigated cell lines.
Selective inhibition of miR-34a with the miRIDIAN inhibitor in A2780 and HTB-77 resulted in a significant 2.3-and 1.5-fold upregulation of E2F3a, respectively, whereas induction of miR-34a yielded a significant E2F3a depletion (Figures 4a and b) . Of special note is that miR-34a-related modulation of E2F3b did not reach statistical significance.
Clinical relevance of miR-34a in ovarian cancer
The negative correlation between E2F3a and miR-34a expression in our patient collective and the regulatory MiR-34a promoter methylation was not detected in the control tissues, but was demonstrable exclusively in cancer specimens. The methylation status of miR-34a positively correlated with grading (r ¼ 0.366, P ¼ 0.001). In univariate survival analyses, miR-34a below the median was associated with poor PFS (P ¼ 0.005) and OS (P ¼ 0.01) (Figures 4e and f) . No significant difference in survival was shown with regard to the methylation status of the miR-34a promoter. Expression of miR20a or miR-210 neither correlated significantly 6p22 amplification in ovarian cancer As gene locus amplification at 6p22 was shown to be involved in aberrant E2F3 overexpression in urogenital cancer, we assumed that this could also be true in ovarian cancer, specifically for the proliferation-promoting 3a isoform. Therefore, ovarian cancer cell lines showing different expression of E2F3a mRNA were subjected to 6p22 fluorescence in situ hybridization (FISH) analyses. Highly-6p22-amplifying bladder cancer cell lines HTB-5 and HTB-9 were used as reference (Bruch et al., 2000) . Two ovarian cancer cell lines, namely HTB-77 and HOC-7, showed 6p22 tetraploidization, whereas A2780 and SKOV-6 were diploid (Figure 5a ). In addition, E2F3a levels were higher in the tetraploid ovarian cancer cell lines compared with that in cells showing diploidy (Figure 5b ). Constitutive E2F3a expression in HTB-5 and HTB-9 exceeded by far the mRNA levels obtained in the ovarian cancer cell lines (Figure 5b ). In ovarian cancer cells E2F3b expression was not mirrored by the 6p22 amplification status. In contrast to these in vitro results, 6p22 polyploidy (46 copy numbers) was found in a significant number of primary tumors (Figure 5c ). Interestingly, in the subgroup of tumors showing high E2F3a levels without demonstrable EGFR activation, 6p22 amplification was detected in 10 (75%) of 14 specimens, as compared with a Clinical impact of E2F3a in ovarian cancer D Reimer et al in univariate analysis, was calculated to assess their independent predictive value. Neither miR-34a expression nor activated EGFR status retained independent prognostic relevance. Beyond residual disease and patient age at diagnosis, only E2F3a expression turned out to be of independent prognostic relevance for both PFS and OS (Table 3) .
Discussion
Based on in vitro data we recently reported on the pivotal role of E2F3a upregulation in EGFR-mediated mitogenic response in ovarian cancer cells (Reimer et al., 2010) . This work aimed to validate the clinical relevance of that integral axis but also of alternative regulatory mechanisms of the transcription factor E2F3a in a cohort of 130 ovarian cancer patients. In keeping with the results obtained from ovarian cancer cell lines and primary cultured healthy ovarian surface epithelial and mesothelial cells, both E2F3a and E2F3b were found to be overexpressed in ovarian cancers as compared with normal ovarian tissue. These findings are in agreement with earlier data showing both proliferation-promoting and -inhibiting E2F family members to be overexpressed in ovarian cancer specimens (Reimer et al., 2007) . Nevertheless, E2F3a expression by far exceeded that of E2F3b in the cancer tissues. By contrast, E2F3b was the predominant E2F3 isoform expressed in healthy ovarian tissues. These observations would argue in favor of a shift toward a predominant expression of E2F3a during malignant transformation. The findings that only elevated E2F3a levels were associated with a higher malignant phenotype, together with the independent prognostic relevance of E2F3a for PFS and OS, underline the pivotal role of E2F3a upregulation in ovarian cancer biology. This is in line with Chen et al., who demonstrated the high oncogenic potential of E2F3a as compared with a weak oncogenicity of the other E2F isoforms (Chen and Wells, 2007) . On the other hand, we found E2F3a expression to be equally distributed among the various histological subtypes. This tempts us to assume that the constitutive E2F3a regulation is not dependent on histological type. This is especially noteworthy as in our collective the proportion of mucinous cancers is relatively high compared with other published series.
The high positive correlation between activated EGFR and E2F3a expression levels implies that in a significant number of ovarian cancers E2F3a upregulation is mediated at least in part by EGFR signaling. The fact that both E2F3a expression and activated EGFR were shown to be associated with poor clinical outcome in univariate survival analyses, but only E2F3a retained independent prognostic significance in the multivariate Cox regression, may point to the existence of alternative mechanisms able to regulate E2F3a beyond EGFRmediated E2F3a control.
Indeed, in 11% of the cancers showing high E2F3a levels without demonstrable activation of the EGFR, we were able to identify two alternative regulatory mechanisms to explain this EGFR-independent elevation of E2F3a transcripts. Furthermore, we identified a significant number of cancers in which it became obvious that alternative E2F3a-regulatory mechanisms and EGFR-dependent E2F3a modulation coexist. The epigenetic control by promoter methylation of miR34a, which has been shown to repress E2F3a expression (Welch et al., 2007) , was showed to be such a putative mechanism. In 73% of the cancers with an uncoupled EGFR-E2F3a axis, CpG methylation was demonstrable in the promoter of miR-34a. In agreement, miR-34a gene silencing by CpG methylation was recently shown in other tumor entities (Lodygin et al., 2008) . In fact, 5-AZA treatment of ovarian cancer cells yielded a significant demethylation of the miR-34a promoter and induction of miR-34a expression, causing a considerable decrease in E2F3a. To exclude that changes in E2F3a expression are caused by unspecific epiphenomena due to global DNA demethylation, ovarian cancer cells were subjected to selective miR-IDIAN-based miR-34a depletion (or induction). These investigations highlight miR-34a to be a substantial negative regulator of E2F3a in ovarian cancer. By this approach we are, however, not able to entirely exclude that other mechanisms related to the demetylating effect of 5-AZA were additionally involved in the decrease of E2F3a expression. E2F3b, which shares the same 3 0 -untranslated region with E2F3a, was also shown to be modulated to a minor extend by miR-34a in our experiments. In line with these in vitro findings, miR-34a In this context it was previously shown that miR-34a expression is directly inducible by p53 and putatively involved in G 1 arrest and apoptosis (Tarasov et al., 2007) . Accordingly, we found that ovarian cancers with documented inactivating p53 mutations were associated with significantly lower levels of miR-34a and higher levels of E2F3a than were p53 wild-type tumors. On the other hand, methylation of the E2F3a promoter itself was detectable in only one tumor in our collective, suggesting that this epigenetic mechanism has no relevant role in ovarian cancer. This is further corroborated by the fact that 5-AZA treatment did not enhance, but in contrast reduced, E2F3a expression in the ovarian cancer cell lines.
Gain and amplification at gene locus 6p22 have been reported as a recurrent abnormality in human bladder cancer (Koo et al., 1999; Simon et al., 2000) . Initial mapping studies indicated that the 6p22 amplicon spanned the SOX4, PRL and E2F3 genes (Veltman et al., 2003) , and E2F3 overexpression based on 6p22 amplification was shown to be correlated with high tumor grade and invasive tumor phenotype in urogenital cancers (Feber et al., 2004; Oeggerli et al., 2004) . In ovarian cancer we showed 6p22 tetraploidization in two cell lines, namely HTB-77 and HOC-7, and evidenced that within these cells constitutive E2F3a expression was significantly higher as compared with that in cells showing 6p22 diploidy. By contrast, E2F3b expression was not found to be mirrored by the 6p22 status. Thus, we here showed for the first time that in ovarian cancer amplification of gene locus 6p22 is associated with a constitutive overexpression of the cell-cycle-promoting 3a isoform of the E2F family. In addition, we were able to detect a particularly high rate of 6p22 amplifications in cancer specimens showing high E2F3a levels independently of EGFR activation, which could be taken into account to explain EGFR-independent E2F3a induction.
However, in the multivariate Cox regression analysis calculated for all the factors involved in E2F3a regulation, such as EGFR activation and miR-34a expression, only E2F3a itself retained independent prognostic significance with regard to PFS and OS. This clearly underlines the key role of E2F3a as an integrative factor in directing cell-cycle progression and ovarian cancer cell proliferation. Of course, the possibility that beyond the herein described mechanisms there exist additional pathways decisively involved in the regulation of E2F3a cannot be excluded. Moreover, at the present time it remains unclear whether the particular clinical value of E2F3a and the mechanisms involved in its regulation are also applicable for other tumor entities or whether they are specific for ovarian cancer.
Taken together, the herein presented findings emphasize the in vivo relevance of the transcription factor E2F3a in ovarian cancer biology. In a significant number of ovarian cancers, regulation of E2F3a expression appears to fit into the concept of the integral EGFR-E2F3a. However, in a considerable subgroup of ovarian cancers, E2F3a levels were shown to not be exclusively linked to EGFR signaling, and these cases may be cancers where classical EGFR drug targeting is not an efficient treatment. In addition to the clinical importance of the EGFR-mediated E2F3a regulation, we here identify two additional mechanisms that are highly relevant in E2F3a government in ovarian cancer, namely expression of miR-34a predominantly controlled by DNA methylation and gene amplification at locus 6p22. Our findings that these mechanisms leading to high E2F3a expression frequently coexist and complement EGFR activation, may explain why a single EGFR targeting proved to be of minor efficiency in ovarian cancer patients.
This issue certainly deserves further in-depth investigation and in future could be important in predicting the responsiveness of EGFR-based targeted therapies, similar to the reported KRAS mutations in colorectal cancer (Van Cutsem et al., 2008) . As E2F3a was shown to be a central cornerstone in the mitogenic signaling in ovarian cancer cells and its clinical impact has now been proven in a cohort of 130 patients, this molecule could pose an appealing new therapeutic target, beyond conventional targeting of the EGFR itself.
Materials and methods

Patients
Tissue samples from patients (n ¼ 130) with invasive, epithelial ovarian cancer were collected during primary surgery at the department between 1998 and 2006. Tumors with borderline malignancy were excluded. Ovarian tissue samples obtained from postmenopausal patients during surgery for other than inflammatory or malignant conditions served as control (n ¼ 35). All included patients gave written informed consent for tissue use in research, and the study was approved by the local Institutional Ethics Review Board. The clinicopathological characteristics are summarized in Table 4 . To detect inactivating p53 mutations in ovarian cancer specimens, the functional yeast-based assay was used as previously described by Concin et al. (2005) .
Cell culture and 5-AZA treatment The ovarian cancer cell lines A2780, HTB-77 and HOC-7 (ATCC/LGC Promochem GmbH, Wesel, Germany) were cultured as previously described by Reimer et al. (2010) . For demethylation, cells were incubated for 5 days in 2.5 mM 5-AZA, or left untreated. Alternatively, cells were incubated with 100 mng/ml TSA alone or together with 5-AZA for the same time period. Cells were then collected and used for subsequent total RNA extraction or genomic DNA isolation.
miRNA transfection A2780 and HTB-77 cells were transfected in 12-well plates (1 Â 10 5 cells per well) with 50 nM miRIDIAN hsa-miR-34a
Mimic or Hairpin Inhibitor (Dharmacon, Lafayette, CO, USA). Control groups were treated with transfection reagent alone (mock transfection), miRIDIAN miRNA inhibitor-negative control or Mimic-negative control. Transfection was performed using the DharmaFECT Duo Transfection Reagent (Dharmacon) according to the manufacturer's instructions. After 48 h of transfection, RNA was isolated using the RNeasy Micro kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol, and the expression of selected genes was analyzed by reverse transcription (RT)-PCR as described below. Changes in c-met mRNA levels based on miR-34a modulation served as control.
Total RNA extraction and real-time PCR amplification Total RNA extraction from cell lines or patient samples, DNAse treatment and reverse transcription were performed as previously described by Reimer et al. (2007) . RT-PCRs were performed using an ABI Prism 7900 Detection System as described previously by Reimer et al. (2010) . PCR assays were conducted in triplicate and the mean value was used for calculation. The primer and probes are given in Supplementary  Table 1 . Gene expression levels were determined by the comparative C T method according to User Bulletin 2 (Applied Biosystems, Foster City, CA, USA). The transcript levels of the genes of interest detected in cell lines or patient samples were normalized to TBP.
Total RNA extraction and real-time PCR of reverse-transcribed miRNAs Paraffin-embedded tissue was available from 120 patients (92.2%). After removal of 1 mm cores from a representative tumor area using a punch biopsy device (Miltex Inc.) RNA was extracted using the RecoverAll Total Nucleic Acid Isolation kit. Primer sets for hsa-miR-34a, miR-20a and miR-210, and endogenous control let-7a were used following the manufacturer's protocol (Applied Biosystems 
DNA isolation and methylation analyses
Genomic DNA from cell lines and patients was isolated using the DNeasy Tissue Kit (Qiagen, Hilden, Germany). Bisulfite modification was performed using the EZ DNA MethylationGold Kit (Zymo Research, Orange, CA, USA) according to the manufacturer's instructions. MethyLight analysis was performed as previously described by Eads et al. (2000) . Two sets of primers and probes designed specifically for bisulfite-converted DNA were used: a methylated set for the gene of interest and a reference set, COL2A1, to normalize for input DNA. Specificity of the reactions for methylated DNA was confirmed separately using SssI (New England Biolabs, Frankfurt, Germany)-treated human white blood cell DNA (heavily methylated). The percentage of fully methylated molecules at a specific locus was calculated by dividing the GENE:COL2A1 ratio of a sample by the GENE:COL2A1 ratio of SssI-treated controls and multiplying by 100. The primers and probes are listed in Supplementary  Table 1 . CpG islands in the analyzed genes were identified using a CpG island searcher (www.uscnorris.com/cpgislands/ cpg.cgi) (Takai and Jones, 2003) .
Immunohistochemistry
Immunohistochemical staining was performed on paraffinembedded 4-mm sections of a tissue microarray using the UltraView Universal DAB Detection kit (Ventana, Tucson, AZ, USA) based on a mouse anti-rabbit Ventana BenchMark automated slide-staining system. As dictated by the availability of tissue specimens, the final array was generated from 92.2% of the patients included in this study, and the tissue microarray was constructed as previously described by Bubendorf et al. (2001) . After deparaffinization antigens were retrieved with cell-conditioning solution-1 (standard); slides were then incubated for 1 h at 37 1C with the rabbit polyclonal anti-Phospho-EGF (Tyr 845) (Cell Signaling Technology, Danvers, MA, USA) (1:50).
Counterstaining was performed using Nexes Hematoxylin (1:2), followed by Nexes Bluing Reagent. Negative controls were obtained by omitting the primary antibody, and paraffinembedded, EGF-treated HTB-77 cell pellets served as positive control. The amount of activated EGFR was independently evaluated by two pathologists. Expression was determined by calculating a total staining score defined as the product of the percentage of stained cells and the staining intensity (0-3). 
FISH analysis for detection of 6p22 E2F3 amplification
Interphase FISH analysis was performed on cell nuclei preparations from tumor blocks, ovarian cancer cell lines (HTB-77, SKOV-6, HOC-7, A2780) and the 6p22-amplifying bladder cancer cell lines HTB-5 and HTB-9. Nuclei were isolated from 20-mm paraffin sections as previously described by Krugmann et al. (2004) : After de-waxing with xylene and rehydration in a graded series of ethanol, four sections were digested in 0.005% proteinase-K (pH 7.5) for 30-60 min at 37 1C and mechanically disaggregated by pressing through a nylon mesh. The isolated nuclei were sedimented by centrifugation, washed and suspended in phosphate-buffered saline, and finally spotted onto slides and air-dried. Dual-color hybridization on pepsin-pretreated nuclei preparations, detection and fluorescence microscopy were performed according to standard FISH protocols using as probes the two 6p22.3-specific biotin/digoxygenin-labeled PAC clones RP11-424H23 (green) and RP11-204E9 (red) that map 320-kb proximal to E2F3. The number of fusion signals was enumerated from 50 nuclei per case and amplification (Gain) was defined as presence of at least six fusion signals in more than 10% of nuclei.
Statistical analysis
Differences in mRNA expression levels were evaluated by comparison of mean values of three independently performed experiments using the Student's t-Test. Differences between normal and malignant tissues, and inter-group differences in clinicopathological characteristics according to E2F3a and E2F3b expression levels, were evaluated with the MannWhitney U-test or the Kruskal-Wallis test. Data were expressed as median and interquartile range. Correlation analyses were performed using the Spearman rank-correlation test. Survival analyses for PFS and OS were conducted by the Kaplan-Meier method, and differences between groups were determined with a log-rank test. To assess the predictive value of E2F3a and E2F3b expression, the Cox proportional hazard model was used with adjustment for confounding variables. The SPSS for Windows 18.0 software (SPSS Inc., Chicago, IL, USA) was used for all analyses.
